Congratulations to Dr. Kucinski as this year’s winner of the SfN Poster of the Year Award for the most interesting work presented using ATS products. You can read a summary of this work from Dr. Sarter’s lab in the cover article in this issue of Targeting Trends. Here is a small sample of the comments […]
Targeting Article: Society for Neuroscience Poster of the Year Award Read More »
by Aaron Kucinski (Collaborators at University Michigan, Ann Arbor: K. Phillips, R. Albin, M. Sarter) In addition to the primary disease-defining symptoms that result from extensive loss of nigrostriatal dopaminergic neurons, approximately half of patients with Parkinson’s Disease (PD) suffer from postural instability, impairments in gait control and a propensity for falls. These symptoms have
Read the 2014 Newsletters and recent scientific references 2014, issue 1: 2014, issue 2: 2014, issue 3: 2014, issue 4:
Targeting Trends 2014 Newsletter Read More »
Congratulations to this year’s winner of ATS’ Poster of the Year featuring IT-42 Anti-ChAT-SAP. Be sure to check out the featured article in Targeting Trends. 692.21 Impairments in gait, posture and complex movement control in rats modeling the multi-system, cholinergic-dopaminergic losses in PDK Phillips, A Kucinski, R Albin, M Sarterfeaturing IT-42 Anti-ChAT-SAP (poster; Wednesday, Nov. 19,
SFN Poster of the Year 2014 Read More »
ATS is pleased to announce Beta-release of a wide array of targeted toxins for use in eliminating specific cell types. This Beta-Testing Program will make new conjugates available to our customers sooner. Each of the Beta products will have: Saporin activity confirmed, Peptide sequences published/confirmed, and/or Antibody binding specificity published/confirmed. Beta Products have not been
Targeting Tools: Beta Testing Program Read More »
Targeted conjugates are widely used to escort payloads to specific cell populations in vitro and in vivo for both basic research and pharmaceutical development. Desirable traits of a Targeting Agent include high specificity and rapid internalization. The Targeting Agent can be an antibody, peptide, protein, or any other molecule that recognizes a cell- surface marker.
Targeting Tools: ZAP Biotin-Z Internalization Kit Read More »
Dog with bone cancer jumps for joy over new treatment that made him pain-free after one dose! Otis, the golden retriever, was in his golden years when bone cancer pain threatened to shorten his life. As a participant in a clinical trial aimed at pet dogs, he was given a single treatment with a pain
Otis Gets His Wag Back! Read More »
Based on the recent publication by: Brown DC, Agnello K. (2013) Intrathecal substance p-saporin in the dog: efficacy in bone cancer pain. Anesthesiology 119(5):1178-1185 and the October 2013 press release by the American Society of Anesthesiologists, “Man’s best friends’ chronic pain relieved with new treatment, study finds: Findings could be useful to human cancer patients.”